COMPANY RESEARCHGyre completed its acquisition of Cullgen on 2026-05-04; they are consolidated into one company record.
The approximately $300 million all-stock acquisition consideration in 2026 is not treated as new financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Gyre completed its acquisition of Cullgen on 2026-05-04; they are consolidated into one company record.
August 2026 update: CG001419 completed a healthy-volunteer Phase 1 pain study; Phase 2 in pain remained planned, while oncology Phase 1 continued. CG009301 is in Phase 1 for hematologic malignancies.
The proprietary uSMITE platform has collaboration and option arrangements with Astellas.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| CG001419 | TRK · See individual trial / indication; not individually confirmed in this review | Phase 1 | Human results reported by the source; see facts and original materials for type and quality |
| CG009301 | GSPT1 · See individual trial / indication; not individually confirmed in this review | Phase 1 | Human results reported by the source; see facts and original materials for type and quality |
| CG923308 | CDK2-CyclinE · See individual trial / indication; not individually confirmed in this review | Preclinical | Human results reported by the source; see facts and original materials for type and quality |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
